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Abstract
Objective: Peripheral arterial disease (PAD) often hinders the cardiac rehabilitation program. The aim of this study was
evaluating the relative cost-effectiveness of new rehabilitation strategies which include the diagnosis and treatment of PAD
in patients with coronary artery disease (CAD) undergoing cardiac rehabilitation.
Data Sources: Best-available evidence was retrieved from literature and combined with primary data from 231 patients.
Methods: We developed a Markov decision model to compare the following treatment strategies: 1. cardiac rehabilitation
only; 2. ankle-brachial index (ABI) if cardiac rehabilitation fails followed by diagnostic work-up and revascularization for PAD
if needed; 3. ABI prior to cardiac rehabilitation followed by diagnostic work-up and revascularization for PAD if needed.
Quality-adjusted-life years (QALYs), life-time costs (US $), incremental cost-effectiveness ratios (ICER), and gain in net health
benefits (NHB) in QALY equivalents were calculated. A threshold willingness-to-pay of $75 000 was used.
Results: ABI if cardiac rehabilitation fails was the most favorable strategy with an ICER of $44 251 per QALY gained and an
incremental NHB compared to cardiac rehabilitation only of 0.03 QALYs (95% CI: 20.17, 0.29) at a threshold willingness-to-
pay of $75 000/QALY. After sensitivity analysis, a combined cardiac and vascular rehabilitation program increased the
success rate and would dominate the other two strategies with total lifetime costs of $30 246 a quality-adjusted life
expectancy of 3.84 years, and an incremental NHB of 0.06 QALYs (95%CI:20.24, 0.46) compared to current practice. The
results were robust for other different input parameters.
Conclusion: ABI measurement if cardiac rehabilitation fails followed by a diagnostic work-up and revascularization for PAD if
needed are potentially cost-effective compared to cardiac rehabilitation only.
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Introduction
Coronary artery disease (CAD) is the leading cause of mortality
and morbidity in the United States[1]. Millions of Americans have
a history of myocardial infarction or experience angina pec-
toris[1]. Many of these patients (on average 300 000 per year)
enter a rehabilitation program and those who have undergone re-
vascularization procedures undergo cardiac rehabilitation with the
objective of improving exercise tolerance, symptoms, serum lipid
levels, and psychosocial well-being, while reducing cardiac risk
factors and mortality[2,3]. Published guidelines for cardiac
rehabilitation and secondary prevention programs advocate a
multifaceted program that includes a monitored 12 weeks exercise
training of 36 sessions (3 sessions per week) and the pursuit of
modifiable risk factor reduction through education, counseling,
reinforcement of medical therapies, behavior change and
acceptance of personal responsibility on the part of the patient[4].
Patients with CAD, however, frequently have peripheral arterial
disease (PAD)(range 19%–42%)[5,6], of whom approximately
50% are symptomatic [5]. PAD hinders the cardiac rehabilitation
program because patients are unable to achieve their target heart
rate due to their limited walking distance. Almost half of the
patients who start cardiac rehabilitation do not complete the
program successfully[7], in large part due to the presence of PAD,
and these patients are at increased risk for cardiac events during
follow-up (20%–60% increased risk for MI)[8,9]. Measurement of
the ankle-brachial-index (ABI) at rest and post exercise is
recommended as the initial screening test to make the diagnosis
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e3883of PAD and using this to decide whether patients need a workup
for PAD either if rehabilitation fails or prior to the rehabilitation
program to improve the results of the program.
The aim of the present study was to evaluate the effectiveness,
costs, and relative cost-effectiveness from the societal perspective of
new rehabilitation strategies which include the diagnosis and
treatment of PAD in patients with CAD undergoing cardiac
rehabilitation.
Methods
Model structure
A Markov decision model was developed to compare current
cardiac rehabilitation with new rehabilitation strategies for
patients with CAD[10,11]. Our primary cohort for analyses (the
base-case) consisted of 64-year old male patients who entered a
cardiac rehabilitation program.
The strategies in the model were 1. Cardiac rehabilitation only;
2. Cardiac rehabilitation; if rehabilitation fails ABI measured at
rest and post exercise and if needed a diagnostic work-up and
revascularization for PAD, after which cardiac rehabilitation is
continued; 3. ABI measured at rest and post exercise and if needed
a diagnostic work-up and revascularization for PAD prior to
cardiac rehabilitation, after which the rehabilitation is started.
Figure 1 shows a schematic representation of the model. In the
cardiac rehabilitation strategy, patients entered the program which
they either completed successfully or they failed. If failure occurred
due to PAD, no intervention took place and patients were followed
in the outpatient clinic. Cardiac rehabilitation failure was defined
as a discontinuation of the treadmill exercise program of 32
sessions or inability to reach target heart rate (individually
determined during a stress test prior to cardiac rehabilitation). In
follow-up, patients experienced a fatal or non-fatal cardiac event
(i.e., defined as acute angina or non-fatal myocardial infarction) or
they died from non-cardiac causes.
In the second strategy, patients also entered a cardiac
rehabilitation program but now if patients failed, an ABI
measurement at rest and post exercise was performed followed
by diagnostic subtraction angiography or magnetic resonance
angiography (proportion 1:1) if PAD was present. Next, the lesion
was treated with percutaneous intervention or bypass surgery
depending on disease severity and level of disease. Suprainguinal
percutaneous transluminal angioplasty (PTA) with stent place-
ment, aorto-iliac grafting, infrainguinal PTA, and femoro-popliteal
bypass were modelled as revascularization procedures. After
revascularization, some patients had complications or procedural
failures and were unable to continue cardiac rehabilitation,
whereas most patients continued with their cardiac rehabilitation
program.
In the third strategy, all patients underwent an ABI measure-
ment at rest and post exercise prior to cardiac rehabilitation. If
patients had symptomatic PAD, a diagnostic work-up and
Figure 1. Schematic simplified representation of the Markov model. It shows three different rehabilitation strategies. Every strategy contains
health states in which a patient can remain for more than one cycle. The health states are pre-rehabilitation (from which every patient starts),
successful rehabilitation, failed rehabilitation, post non-fatal cardiac event, and death (i.e. cardiac death or non-cardiac death). All health states are
only demonstrated in the upper strategy for simplification. MI=Myocardial infarction; PAD=peripheral arterial disease; CAD=coronary artery disease;
ABI=ankle brachial index.
doi:10.1371/journal.pone.0003883.g001
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to cardiac rehabilitation.
For each of the three strategies, the model kept track of time and
costs spent in one of the following health states: (a) pre-
rehabilitation; (b) successful rehabilitation; (c) failed rehabilitation;
(d) post non-fatal cardiac event; and (e) cardiac death or non-
cardiac death. A Markov cycle tree was updated every 6 months
after which patients’ clinical status and costs were estimated to
model life-time health benefits and costs.
Data Sources
Effectiveness and cost data for the model were retrieved from
the literature and from primary data collection. Table 1 and 2
show estimates from the best-available evidence of the included
variables with probability distributions representing the uncertain-
ty around the estimates and the data sources
[5,6,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,3-
1,32,33,34,35,36,37,38,39,40,41,42,43,44,45]. Original patient
data was collected in Lutheran General Hospital, Chicago, U.S.,
and included data from 231 consecutive men and women who
started cardiac rehabilitation from January 2004–December 2004.
Of the 231 patients, 125 patients (54%) completed cardiac
rehabilitation successfully, 97 patients (42%) failed cardiac
rehabilitation, and 9 patients (4%) were lost to follow-up. Of
those 125/(125+97)=56% who were not lost to follow-up
completed rehab successfully, and the assumption is made that
loss-to-follow-up status did not affect the chance of completing
cardiac rehabilitation.
Effectiveness
In addition to estimates derived from the literature and the
hospital database that were included directly in the model, some
estimates were recalculated and several assumptions were needed.
Hazard rates for fatal- and non-fatal cardiac events during follow-
up for patients with and without cardiac rehabilitation, were
calculated from probabilities derived from representative studies
(i.e., those who compared cardiac rehabilitation to lifestyle changes
only) which were included in a systematic review of Taylor and
colleagues (Table 1)[16].
Long-term life expectancy was calculated on the basis of age-
and sex-specific mortality rates from standard U.S. life-tables of
the general population[35]. In addition, life-expectancy was
adjusted for quality of life (i.e., Quality-Adjusted-Life Years
(QALYs) using health-related quality-of-life weights (Table 2).
To estimate the quality-of-life weight prior to rehabilitation and
for successful completion of the program, we used the weighted
average of health-related quality-of-life weights based on the
literature[12,36]. For patients who failed cardiac rehabilitation,
quality-of-life weights were not available. We assumed that these
patients had the same quality of life as prior to rehabilitation as
they did not experience any benefit from the program (Table 2).
The proportion of patients who failed cardiac rehabilitation due
to PAD was based on the ABI measured in a subset of our patient
sample and based on data retrieved from the literature [5,6]. All
231 patients were invited to the hospital for additional testing on a
specific date, of which 39 patients responded. The patient
characteristics between the subset and the non-responders were
not statistically different (p.0.05). In the responders, the ABI was
measured and PAD was defined as an ABI less than 0.90 [46]. The
leg with the lowest ABI was used in the analyses.
In our patient sample, 7 out of 39 patients (18%) failed cardiac
rehabilitation due to PAD, whereas of all patients who failed
cardiac rehab (44%), there was 40% probability that PAD is the
cause of cardiac rehab failure (i.e., 18%/44%=40%). In strategies
that included revascularization for PAD, we assumed that in the
majority of patients (95%) revascularization was possible and that
90% of these patients would benefit from treatment. In our patient
sample, 7 out of 39 patients (18%) failed cardiac rehabilitation due
to PAD, therefore we modelled that 15% (i.e., 18% * 95% * 90%)
underwent successful revascularization for PAD and subsequently
continued their cardiac rehabilitation program. Thus, including
the possibility of revascularization for PAD in the cardiac
rehabilitation strategy, in total 71% (i.e., 56% plus 15%) of all
patients completed the cardiac rehabilitation program successfully.
Costs
Costs included in the model incorporated medical and non-
medical costs and were assessed from the societal perspective
(Table 2). Medical costs included costs of all diagnostic and
therapeutic procedures, cardiac rehabilitation, costs for personnel,
materials, equipment, associated hospital admissions during 6
months follow-up, and overhead. These costs were derived from
the financial department of Lutheran General Hospital.
Non-medical costs included transportation costs and patient
time costs. Transportation costs included parking costs and mean
estimated gasoline costs. Patient time costs were determined by
multiplying the hourly wage rate ($18.55/hour) by the number of
hours or days spent in the hospital[47]. Time spent in the hospital
was derived from our hospital database (e.g. cardiac rehabilitation
36 hours (60 min636 sessions) and a bypass procedure was on
average 6.5 days).
Costs of cardiac rehabilitation only included scheduled cardiac
rehabilitation visits, a stress test, follow-up visits, transportation
costs, and patient time costs.
To take into account time preference, future costs were
discounted at the currently recommended nominal discount rate
of 3% per year[48]. All costs were converted to the year 2005 U.S.
dollars by using the medical care specific consumer price index
obtained from the Bureau of labour Statistics[47].
Analysis
Quality-adjusted-life expectancy, life time costs, and incremen-
tal cost-effectiveness ratios (i.e., additional costs divided by quality-
adjusted-life-years gained) were calculated for all three strategies.
Strategies were ordered according to increasing effectiveness
(QALYs). A strategy was considered dominated if another strategy
was both more effective and less costly. A strategy was considered
extended dominated if another strategy achieved more effective-
ness at a lower incremental cost-effectiveness ratio. After
eliminating dominated and extended dominated strategies the
incremental cost-effectiveness ratios (ICERs) were calculated as the
difference in mean lifetime costs divided by the difference in mean
QALYs for each strategy compared to the next best non-
dominated strategy[49].
Furthermore, we transformed costs and QALYs into one
comprehensive outcome measure: the net health benefit
(NHB)[11,50,51]. The NHB was defined as lifetime effectiveness
(QALYs) minus lifetime costs ($), the latter divided by the societal
willingness-to-pay (WTP) threshold to save one QALY ($/QALY).
The NHB is expressed in QALY-equivalents. Published estimates
for WTP ranged from $20 000 to $100 000 per QALY gained. In
our analysis we considered $75 000 per QALY gained as a
commonly accepted threshold and varied the WTP between
$50 000 and $100 000 in sensitivity analyses[51,52]. For each of
the two new strategies considered we calculated the gain in NHB
compared to the NHB of cardiac rehabilitation only [53].
To explore the effect of uncertainty in our parameter estimates,
we performed extensive one-way, two-way, and multi-way
Cardiac Rehabilitation
PLoS ONE | www.plosone.org 3 December 2008 | Volume 3 | Issue 12 | e3883Table 1. Data included in the Markov model on rehabilitation strategies for patients with coronary artery disease.
Variable Base Case Value Distribution 95% CI
1 Literature or Database Source
Probabilities cardiac rehabilitation
Success current cardiac rehabilitation 0.56 Beta 0.13, 0.93 ALGH
Success cardiac rehabilitation after treatment PAD 0.71 Beta 0.22, 0.99 see text
Failure cardiac rehabilitation due to symptomatic PAD 0.18 Beta 0.04, 0.41 ALGH
PAD is cause after failure cardiac rehabilitation 0.40 Beta 0.09, 0.75 ALGH
Symptomatic PAD among cardiac rehabilitation patients 0.26 Beta 0.06, 0.54 ALGH, [5,6]
6-month rates of events during follow-up
Cardiac event after rehabilitation (fatal and non-fatal) 0.03 Beta 0.02, 0.04 [16], see text
Cardiac event without rehabilitation (fatal and non-fatal) 0.05 Beta 0.03, 0.05 [16], see text
Fatal cardiac event after rehabilitation 0.01 Beta 0, 0.05 [16], see text
Fatal cardiac event without rehabilitation 0.03 Beta 0, 0.07 [16], see text
Probabilities PAD status
Suprainguinal disease conditional on the presence of PAD 0.56 Beta 0.01, 0.99 [17]
Suprainguinal lesion is suitable for angioplasty 0.51 Beta 0.36, 0.66 [15,17]
Infrainguinal lesion is suitable for angioplasty 0.18 Beta 0.04, 0.41 [15,17]
Lesion is suitable for surgery
{ 0.95 Beta 0.82, 0.99 see text
Aorto-iliac lesion is occlusive vs. stenotic 0.20 Beta 0.01, 0.54 [18]
Femoro-popliteal lesion is occlusive vs. stenotic 0.36 Beta 0.01, 0.89 [14]
Vein is available for bypass surgery vs. PTFE is required 0.20 Beta 0.01, 0.53 ALGH
Mortality rate for PAD procedures and imaging
Iliac PTA with selective stent placement 0.005 Beta 0, 0.01 [32,38,42]
Femoral or popliteal PTA 0.005 Beta 0, 0.01 [41,45]
Aortic bifurcation grafts 0.02 Beta 0, 0.04 [40,43]
Femoro-popliteal or infrapopliteal bypass 0.026 Beta 0, 0.05 [44]
Diagnostic imaging (angiography and magnetic resonance Imaging) 0.00033 Beta 0, 0.005 [22,23]
Probabilities systemic complications of PAD procedures*
Iliac PTA with selective stent placement 0.007 Beta 0, 0.1 [42]
Femoral or popliteal PTA 0.003 Beta 0, 0.01 [39,41]
Aortic bifurcation grafts 0.02 Beta 0, 0.04 [40]
Femoro-popliteal or infrapopliteal bypass 0.085 Beta 0.02, 0.18 [20]
6-month patency in patients with PAD
Iliac PTA with selective stent placement
{
Stenosis 0.95 Beta 0.85, 0.99 [19]
Occlusion 0.80 Beta 0.58, 0.95 [19]
Femoro or popliteal PTA without stent placement
Stenosis 1.0 Beta 0.95, 1.0 [24]
Occlusion 0.88 Beta 0.83, 0.95 [24]
Femoro or popliteal PTA with stent placement
Stenosis 1.0 Beta 0.96, 1.0 [24]
Occlusion 0.99 Beta 0.95, 1.0 [24]
Aortic bifurcation grafts 0.98 Beta 0.96, 0.9 [25]
Femoro-popliteal or femoroinfrapopliteal bypass
Autologous vein above-knee anastomosis 0.95 Beta 0.86, 0.99 [26,27]
Autologous vein below-knee anastomosis 0.94 Beta 0.85, 0.99 [28]
PTFE, above-knee anastomosis 0.87 Beta 0.92, 0.96 [28,29]
PTFE, below knee anastomosis 0.70 Beta 0.60, 0.79 [28,29]
ALGH: Advocate Lutheran General Hospital; PTFE=Poly Tetra Fluor Ethylene, PTA=Percutaneous Transluminal Angioplasty, PAD=Peripheral Arterial Disease.
*Systemic complication is defined as all events that occurred within 30 days after the procedure and that required additional medical care.
{Patency estimates for iliac PTA with selective stent placement have been shown to equal those for iliac PTA with primary stent placement [29].
{In the Markov model, we assumed that 5% of the lesions were not suitable for surgery.
1numbers are 95% CIs for the beta distributions.
doi:10.1371/journal.pone.0003883.t001
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order Monte Carlo simulation), the uncertainty around the
outcomes of the strategies was assessed [11,54] by picking at
random a value from each of the distributions of the parameter
values, running the model with these values to get one set of
outcome values, and repeating this 100 000 times[10].
Acceptability curves were used to express the uncertainty in the
ICER from the probabilistic sensitivity analyses. These curves
show for each predefined WTP-threshold the probability of cost-
effectiveness for the three different strategies.
In value of information analysis we determined whether more
information from future research is necessary to decrease the
remaining uncertainty[55]. More research is not justified if the
expected costs of further research exceed the expected benefit of
that study. To estimate the total expected value of perfect
information (EVPI) per patient, we calculated for each of the
100 000 Monte Carlo simulations from the probabilistic sensitivity
analysis [53] the NHB of the optimal strategy per simulation,
which is the expected NHB with perfect information. The EVPI is
the difference between the mean expected NHB with perfect
information from the probabilistic sensitivity analysis and the
mean NHB with current information from the primary analysis.
Next, we estimated the population EVPI, which is the total EVPI
per patient multiplied by the expected lifetime of the technology
Table 2. Health related quality of life and costs in U.S. Dollars.
Variable Base Case Value Distribution 95% CIs/ranges
{{ Literature or Database Source
Health-related quality of life weights
Pre-rehabilitation* 0.83 Uniform 0.51, 0.98 [12,36]
After failed cardiac rehabilitation 0.83 Uniform 0.51, 0.98 See text
After successful cardiac rehabilitation 0.98 Uniform 0.80, 0.98 [12,13,30,36]
After non-fatal cardiac event 0.83 Uniform 0.51, 0.98 [12,36]
Systemic complications
{ 0.72 Uniform 0.48, 0.95 [37]
Costs (US Dollars)1
Rehabilitation (6 months)
Scheduled visits cardiac rehabilitation 3 112 Lognormal ALGH
Stress test** 95 Lognormal ALGH
Follow-up visit** 75 Lognormal ALGH
Transportation costs 117 Lognormal ALGH
Patient time costs 481 Lognormal ALGH, [47]
Total costs Cardiac rehabilitation if successfully completed 3 880 Lognormal 1385, 8636 ALGH
Total costs Cardiac rehabilitation if patient failed the program
" 3 289 Lognormal 1201, 7249 ALGH
Post-Program after rehabilitation (per year) 1 257 Lognormal 446, 2800 [31]
Diagnosis for PAD
Ankle-brachial index followed by treadmill walking 35 Lognormal 10, 90 ALGH
Diagnostic angiography/imagingI 778 Lognormal 276, 1732 ALGH
Revascularization for PAD
Aortic bifurcation grafts 32 942 Lognormal 11 711, 73 704 ALGH
Iliac PTA with selective stent placement
{ 9 618 Lognormal 4872, 17 193 [29,32,33]
Femoro-popliteal or infrapopliteal bypass 13 932 Lognormal 5019, 31 453 ALGH
Femoral or popliteal PTA 9 618 Lognormal 1243, 15 159 [33]
Systemic complications after revascularization for PAD
Short-term costs 12 430 Lognormal 3004, 35 600 [33]
Annual long-term costs 13 715 Lognormal 3205, 37 411 [34]
Mortality from revascularization procedures 14 783 Lognormal 3571, 41 108 [33]
Recurrent events
Non-fatal cardiac event first year 18 589 Lognormal 6537, 41 223 [31]
Non-fatal cardiac event annually thereafter 7500 Lognormal 1407, 21 904 [31]
Fatal cardiac event 20 971 Lognormal 7388, 4055 [31]
ALGH=Advocate Lutheran General Hospital; PTA=Percutaneous Transluminal Angioplasty; PAD=Peripheral Arterial Disease.
*Values based on responses on the EuroQol-questionaire [59,60].
{Average Time Trade-off value among survivors of a myocardial infarction, used as a proxy for the effect on quality of life of a systemic complication[37].
{Assumes that in 43% of the cases a stent is placed [29].
1Costs were converted to the year 2005.
"Based on the average number of sessions patients completed in ALGH.
ICosts are average costs of MRA and DSA because they were performed in the same proportion in ALHG.
**Costs are costs per event.
{{numbers are 95% CIs for the lognormal distributions and ranges for the uniform distributions.
doi:10.1371/journal.pone.0003883.t002
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future patients expected to benefit from more research (assumed to
be 300 000, i.e. the annual number of patients who undergo
cardiac rehabilitation in the U.S.) adjusted for the discount
rate[53]. The EVPI expressed in NHB was reframed in terms of
Net Monetary Benefit (NMB=NHB*WTP) which enables
comparison with research costs. The EVPI expressed in NMB is
the maximum amount worth spending on future research to
decrease current uncertainty.
The model was developed in TreeAge (version TreeAge Pro
suite 2007, TreeAge Software, Inc, Williamstown, Mass).
Results
Baseline analysis
Table 3 shows that an ABI measurement if cardiac rehabilita-
tion fails followed by a diagnostic workup and revascularization for
PAD if needed was the most favorable with an ICER of $44 251
per QALY gained. The NHB of this strategy was 3.38 (95% CI:
2.68, 3.95) at a WTP of $75 000 (Table 3). Intermediate outcomes
presented in Table 4, showed that in a hypothetical cohort of
10 000 patients, the number of patients with a cardiac event
during follow-up was lowest when an ABI measurement if cardiac
rehabilitation fails was performed followed by a diagnostic work-
up for PAD if needed. This benefit was partly diminished,
however, by an increased number of patients with peri-procedural
morbidity and mortality related to the PAD revascularization
procedure.
Sensitivity analysis
In a two-way sensitivity analysis, we varied the success rate of
the cardiac rehabilitation program by assuming that patients
entered a combined cardiac and vascular rehabilitation program.
In this analysis, we assumed that the success rate of current
practice increased by 25%. This assumption was based on an 80%
success rate as a result of the vascular component of the combined
rehabilitation program in patients who would otherwise fail due to
PAD. Thus, in this strategy an additional 14% (i.e., 80% of 18%)
completed the program successfully. Therefore, in total 70% (i.e.,
56% plus 14%) completed the new program successfully; hence,
the increase in success rate of 25% (i.e., 70% versus 56%). This
program would be comparable to the cardiac rehabilitation
program, except for the aim of the program which is here both
improving maximum walking distance and reaching THR by
performing different appropriate exercise modalities. The same
equipment will be used, but physical therapists need to be trained
in order to know how to perform an individualized exercise
prescription for aerobic and resistance training in patients with
both CAD and PAD making the program more expensive ($400
additional costs). The results show, that this combined cardiac and
vascular rehabilitation strategy would dominate the other two
strategies with total lifetime costs of $30 246, a quality-adjusted life
expectancy of 3.84 years and an incremental NHB of 0.06
(95%CI: 20.24, 0.41)compared to current practice.
In another two-way sensitivity analysis we changed both the
‘‘probability that PAD is the cause of cardiac rehabilitation
failure’’ and the WTP value. If the probability would be lower, we
expected that fewer patients would benefit from the strategy ABI if
cardiac rehabilitation fails. Cardiac rehabilitation only was the
preferred strategy below a threshold probability of 0.05 and a
WTP value of $50 000 with a NHB of 3.35 QALYs. Doing a
diagnostic work-up for PAD in all patients prior to the cardiac
rehabilitation program would not be beneficial, which was mainly
due to the higher costs of the diagnostic imaging and due to the
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demonstrated that for a WTP of $50 000 with a 50% increase
in peri-procedural complications, 50% increase that the patient
has PAD, and below a threshold of 0.10 that PAD is the cause of
cardiac rehabilitation failure, cardiac rehabilitation only was the
preferred strategy and performing a diagnostic work-up for PAD
prior to cardiac rehabilitation in all patients was dominated by all
other strategies.
For other parameters, we found that alternative assumptions
either did not substantially affect the outcomes or affected all
strategies similarly. If we lowered, for example, the original
estimated rate of cardiac events after cardiac rehabilitation, the
NHBs decreased for all strategies. Furthermore, varying the costs
of fatal- and non-fatal cardiac events between 50% and 150% of
the original estimates affected all strategies similarly and did not
change the results of the NHBs.
Probabilistic sensitivity analysis and Value of information
analysis
Probabilistic sensitivity analysis demonstrated an incremental
NHB of ABI if rehabilitation fails compared to cardiac
rehabilitation only of 0.03 QALYs (95% CI: 20.17, 0.29), which
implies considerable uncertainty around the outcome. Measuring
the ABI in all patients prior to the rehabilitation program
demonstrated a loss in NHB of 20.22 QALYs (95%CI: 20.49,
20.01) with 100% of the distribution below zero implying that this
strategy is unlikely to ever be cost-effective compared to cardiac
rehabilitation only.
Figure 2 shows the acceptability curves for new cardiac and
vascular rehabilitation strategies for patients with coronary artery
disease. The probability that ABI if rehabilitation fails is cost-
effective increases with an increasing threshold for the ICER. In
the value of information analysis considering all three strategies the
total EVPI per patient was $1 743 using a WTP of $75 000. This
implies that an infinitely large future study is expected to increase
the NMB per patient with $1 743. With the annual estimated
number of patients that undergo cardiac rehabilitation of 300 000,
an effective lifetime of a new rehabilitation strategy of 10 years,
and a discount rate of 3%, the population EVPI was $2.4 billion.
Discussion
In this study, we evaluated whether patients with CAD who
currently enter a cardiac rehabilitation program would benefit
more from the program if treatment for PAD is considered. The
results suggest that a strategy with an ABI measurement if cardiac
rehabilitation fails followed by a diagnostic work-up and
revascularization for PAD if needed was the most attractive. A
strategy that included an ABI measurement in all patients prior to
the cardiac rehabilitation program did not increase QALYs
compared to cardiac rehabilitation only. In a sensitivity analysis
we assumed a combined cardiac and vascular rehabilitation
approach in which we increased the success rate and the costs of
current practice. This new program is expected to be more
expensive but can also potentially prevent additional events in
CAD patients during follow-up due to its higher success rate,
which would lead to a gain in QALYs.
Current rehabilitation programs in the United States and in
Western European countries consist of either cardiac rehabilita-
tion for patients with CAD or vascular rehabilitation for patients
with PAD. A combined program does not exist. Vascular
programs range from hospital-based walking on a treadmill to
home-based walking in the community until a mild or moderate
level of pain is reached. These programs do not induce patients’
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PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e3883target heart rate. We showed that it is attractive to develop a new
rehabilitation program in which cardiac rehabilitation and
vascular programs are combined, or revascularisation for PAD is
considered, to decrease the failure rate of cardiac rehabilitation.
Due to continuously escalating medical costs, third-party payers
demand evidence of cost-effectiveness and cost-related benefits of
health care services and programs. With ABI measurement if
cardiac rehabilitation fails followed by a diagnostic work-up and
revascularization for PAD if needed, many secondary events can
be avoided in patients with CAD. Nevertheless, we must interpret
these results with caution because of the remaining uncertainty in
our analysis. Future clinical research could reduce the uncertainty
and patients could potentially benefit from more precise estimates
of test characteristics, costs, and treatment effects. To assess
whether the remaining uncertainty justifies future research, we
performed a value of information analysis. The large population
EVPI of $2.4 billion suggests that a substantial investment in
future research would be justified.
One of the limitations of this study was that certain assumptions
were needed in evaluating the rehabilitation strategies in a Markov
model, which may have affected our results. For the assumptions,
we specified a broad distribution for this model parameters and
performed second order Monte Carlo simulation to select random
values from this distribution in order to include this uncertainty. In
addition, the available evidence regarding costs and effects was
extrapolated over the entire remaining lifetime of patients. To
explore how changes would affect the lifetime cost-effectiveness,
extensive sensitivity analysis was performed and changing costs or
effectiveness affected all strategies similarly. If we assumed, for
example in our sensitivity analysis, an increase of the success rate
of the cardiac rehabilitation probability by assuming a combined
cardiovascular rehabilitation program, this strategy dominated the
other two strategies. For many other assumptions, we demon-
strated that varying the parameter values did not change the
results substantially or changed the results for all strategies
similarly while the conclusions remained the same. Another
limitation of our study was the small subset of our patient sample
who participated in the follow-up ABI measurement to determine
the percentage failures due to PAD in our study group. However,
the patient characteristics between the responders and non-
responders were not significantly different and varying the
percentage of failures due to PAD in a sensitivity analysis, we
demonstrated that the results remained the same.
Cardiac rehabilitation programs remain underused in many
countries. For example, in the U.S. only 10 to 20 percent of 2
million eligible patients per year who experienced a myocardial
infarction or underwent cardiac revascularization procedures
participated in a cardiac rehabilitation program[2]. Previous
studies reported that factors such as poor patient motivation or co-
existing illnesses were related to non-attendance of the cardiac
rehabilitation program[56,57,58]. Many patients among non-
participants could be physically inactive because of PAD, which
could reduce patient’s motivation to participate in a cardiac
rehabilitation program and emphasizes the need to explore
alternative strategies to diagnose and treat PAD in patients in
cardiac rehabilitation programs.
In conclusion, the results suggest that a more aggressive
approach to the diagnosis and treatment of PAD in CAD patients
undergoing cardiac rehabilitation is warranted. ABI measurement
in patients who fail cardiac rehabilitation followed by a diagnostic
work-up for PAD and revascularization if needed, could
potentially decrease secondary cardiac events and are likely to
be cost-effective compared to cardiac rehabilitation only.
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